[Pfizer is reported to have launched a large bond sale to finance the acquisition of Seagen] Pfizer will sell large amounts of debt to finance the acquisition of Seagen. The bonds have a maximum maturity of 40 years and are expected to yield 1.8 percentage points higher than Treasuries, according to people familiar with the matter. Earlier, Pfizer announced a final merger agreement with biotech company Seagen on March 13. Under the agreement, Pfizer will buy Seagen for $229 a share in cash, with a total enterprise value of $43 billion. The board of directors of the two companies unanimously approved the deal. The two companies are expected to close the deal by the end of 2023 or early 2024, provided that customary closing conditions are met, including approval from Seagen shareholders and receipt of required regulatory approvals. Seagen's risk-adjusted revenue contribution is expected to exceed $10 billion in 2030.